GOVERNANCE

President

Arsela Prelaj, MD, PhD, is a Medical Oncologist and Head of the AI-ON-Lab at Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, specializing in thoracic malignancies and translational immunotherapy, with a research focus on integrating artificial intelligence and multimodal data to predict immunotherapy outcomes in lung cancer.

President-elect

Jakob Kather, MD, MSc, is Professor of Clinical Artificial Intelligence at the Technical University Dresden and senior physician in medical oncology at University Hospital Dresden, specializing in the development of AI and deep learning methods for precision oncology, with a focus on extracting clinically actionable biomarkers from histopathology, radiology, and multimodal clinical data to advance personalized cancer care

General Secretary

Mireia Crispin Ortuzar, PhD, is an Assistant Professor at the University of Cambridge specializing in multi-omic data integration and machine learning to study tumour evolution and treatment response, with a focus on ovarian cancer; she co-leads the Ovarian Cancer Programme at the CRUK Cambridge Centre and serves as Chief Digital Officer at 52 North Health.

Claes Lundström, PhD, is Professor of Medical Visualization at Linköping University and Director of the Analytic Imaging Diagnostics Arena (AIDA), specializing in the development of AI, machine learning, and visualization methods for medical imaging and digital pathology; and has led to both national-scale research initiatives and commercial innovations

Loïc Verlingue, MD, PhD, is a physician-scientist at Centre Léon Bérard in Lyon, France, specializing in early-phase clinical trials, data science, and artificial intelligence in oncology. His research focuses on developing virtual cell systems for drug screening by integrating high-throughput molecular data, and generative AI applications.

Daniel Truhn, MD, MSc, is Full Professor of Radiology at University Hospital RWTH Aachen, where he leads the AI in Medical Imaging group; he is a clinical radiologist, physicist, and imaging scientist specializing in machine learning, multimodal data integration, and generative models for precision oncology and advanced diagnostic imaging.

Vanja Mišković, PhD, is a postdoctoral researcher at Politecnico di Milano and Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, specializing in explainable machine and deep learning for treatment prediction in oncology, with a focus on developing AI frameworks for personalized therapy selection in different cancer types.

Julien Calderaro, MD, PhD, is Professor of Pathology at Université Paris-Saclay and the Pathology Department at Hôpital Henri Mondor, AP-HP, France. He is an internationally recognized expert in liver pathology and computational pathology, with research focusing on integrating artificial intelligence and digital pathology.

Mihaela Aldea, MD, PhD, is an Assistant Professor at Paris Saclay University and a medical oncologist at Gustave Roussy, specializing in thoracic cancers, precision medicine, and liquid biopsy. Her research focuses on molecular profiling and resistance mechanisms in lung cancer, and on AI-driven clinical studies and clinical biomarker identification.

Narmin is a senior AI researcher at the Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Germany. Her work focuses on deep learning, image processing, and histopathology, particularly in the context of cancer research and digital health. She has co-authored influential papers on artificial intelligence in histopathology, LLM in medicine, and decentralized AI for cancer diagnostics

Giovanni is a Senior Project Management Consultant at Waypoint Research Services, where he specializes as a research projects and funding consultant. He has extensive experience in managing EU funding and coordinating large academic research consortia and networks.